A-928605 |
Pre-clinical |
Neuroblastoma |
Abbott |
Dual IGF-IR/IR tyrosine kinase inhibitor |
[283] |
ABDP |
Pre-clinical |
Colon cancer |
AstraZeneca |
Dual IGF-IR/IR tyrosine kinase inhibitor |
[284] |
AG-1024 |
Pre-clinical |
Breast cancer, colorectal cancer, glioma, hepatocellular carcinoma, mesothelioma, NSCLC, osteosarcoma, pancreatic cancer, prostate cancer |
Calbiochem EMD Biosciences |
Tyrosine kinase and autophosphorylation inhibitor |
[268, 285–294] |
BMS-536924 |
Pre-clinical |
AML, breast cancer, ovarian cancer |
Bristol-Myers Squibb |
ATP-competitive inhibitor |
[59, 249, 295] |
BMS-554417 |
Pre-clinical |
Breast cancer, ovarian cancer |
Bristol-Myers Squibb |
Reversible ATP-competitive small molecule inhibitor |
[153] |
GSK1838705A |
Pre-clinical |
Breast cancer, cervical cancer, colon cancer, Ewing sarcoma, glioma, head and neck cancer, hepatocellular carcinoma, lung cancer, NPM-ALK+ T-cell lymphoma, ovarian cancer, PCM, pancreatic cancer, prostate cancer |
GlaxoSmithKline |
Triple IGF-IR/IR/ALK tyrosine kinase inhibitor |
[177, 296–298] |
GSK1904529A |
Pre-clinical |
Askin tumor, breast cancer, cervical cancer, colon cancer, Ewing sarcoma, head and neck cancer, lung cancer, NPM-ALK+ T-cell lymphoma, ovarian cancer, PCM, prostate cancer |
GlaxoSmithKline |
Dual IGF-IR/IR tyrosine kinase inhibitor |
[299] |
INSM-18 |
Pre-clinical |
Prostate cancer |
Insmed |
Dual IGF-IR/HER2 small molecule inhibitor |
[300] |
NVP-ADW742 |
Pre-clinical |
AML, Ewing sarcoma, medulloblastoma, NSCLC |
Novartis |
Reversible ATP-competitive small molecule inhibitor |
[60, 257, 259, 301, 302] |
NVP-AEW541 |
Pre-clinical |
AML, breast cancer, colon cancer, endometrial cancer, esophageal cancer, Ewing sarcoma, gastric cancer, gastrointestinal stromal tumors, glioma, head and neck cancer, hepatocellular carcinoma, medulloblastoma, neuroblastoma, ovarian cancer, pancreatic cancer, PCM, pituitary tumors, prostate cancer, soft tissue sarcomas, synovial sarcoma |
Novartis |
Reversible ATP-competitive small molecule inhibitor |
[56, 57, 61, 218–240] |
Picropodophyllin (PPP; AXL1717) |
Pre-clinical |
Breast cancer, CML, colon cancer, Ewing sarcoma, glioblastoma, hepatocellular carcinoma, lung cancer, MCL, medulloblastoma, neuroblastoma, NPM-ALK+ T-cell lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, PCM, uveal melanoma |
Axelar |
Non-ATP-competitive small molecule inhibitor |
[21–23, 56, 64, 203–216] |